Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDTNFB)

Drug Name

ISIS-STAT3 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting STAT3 messenger RNA (STAT3 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
C188-9	DMOV2ZD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
ISIS 113187	DM4E6Y8	Discovery agent	N.A.	Investigative	[4]
ISIS 113176	DM5QEP4	Discovery agent	N.A.	Investigative	[4]
ISIS 113209	DMGVN7A	Discovery agent	N.A.	Investigative	[4]
ISIS 113210	DMZWH6E	Discovery agent	N.A.	Investigative	[4]
ISIS 17148	DMPZ9D3	Discovery agent	N.A.	Investigative	[4]
ISIS 17152	DME7VZG	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT01563302) Phase 1/2, Open-label, Dose-escalation Study of ISIS-STAT3Rx, Administered to Patients With Advanced Cancers. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.